Maze Therapeutics
MAZE | NASDAQ
$33.90
-$0.43 (-1.25%)
At close: Nov 16, 2026, 4:00 PM ET
$33.58
-$0.32 (-0.94%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Maze Therapeutics Company Profile
Company profile explainedCompany Profile
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Jason V. Coloma | Chief Executive Officer & Director |
| Andrew Good | VP & Corporate Controller |
| Atul Dandekar | Chief Strategy & Business Officer |
| Courtney J. Phillips | General Counsel & Corporate Secretary |
| Harold S. Bernstein | President of Research & Development and Chief Medical Officer |
| Maarten Hoek | Chief Scientific Officer |
| Matt Krause | Senior Vice President of Human Resources |
| Misbah Tahir | CFO & Principal Accounting Officer |
| Nazila Habibizad | Senior Vice President of Technical Operations & Supply Chain |
| Susan Limb | Senior Vice President of Clinical Development |
| Vipin Vijayakumar | Senior Vice President of Technology and Business Operations |
| Winston Tse | Senior Vice President of Drug Discovery |
Maze Therapeutics
| Country | United States |
| IPO Date | Jan 31, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 141 |
| CEO | Jason Coloma |
Contact Details
171 Oyster Point Blvd South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | MAZE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001842295 |
| CUSIP Number | 578784100 |
| ISIN Number | US5787841007 |
| SIC Code | 2836 |
Recent News
- 7 days ago / globenewswire.comMaze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- 13 days ago / zacks.comWall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know
- 14 days ago / globenewswire.comMaze Therapeutics to Participate in Upcoming Investor Conferences
- 29 days ago / zacks.comWhat Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
- 29 days ago / zacks.comHow Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
- 1 month ago / globenewswire.comMaze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
- 2 months ago / fool.comMaze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
- 3 months ago / globenewswire.comMaze Therapeutics to Participate in Three Upcoming Investor Conferences
- 3 months ago / seekingalpha.comMaze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist
- 3 months ago / globenewswire.comMaze Therapeutics Announces Appointments to Its Board of Directors
Add to Watchlist
Select watchlists to add or remove MAZE